Diğer Yayınlar Koleksiyonu
Bu koleksiyon için kalıcı URI
Güncel Gönderiler
Öğe Prognostic role of tumour-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population(Elsevier Science Inc, 2019) Zengin, MelunetAim: Tumour-infiltrating T lymphocytes (TIL) are considered to be a reliable prognostic marker in CC, but the use in daily practice is unclear. We investigated the survival effect of TIL methodologically in a highly homogeneous population. Methods: Seventy-two stage IIA (T3N0) CC patients who underwent surgical resection from 2000 to 2014 were included. CD3 and CD8 were separately scored for different blocks, areas and foci. To the best of our knowledge, this study has the most comprehensive methodology in the literature. Results: Foremost, we searched for the optimal evaluation method. We found better results with Model A (deepest invasive block&hot spot area&invasive margin focus), e.g. for CD3, the relationship with prognostic factors [Crohn's-like reaction (p = 0.015), positive surgical margin (p = 0.019), Mismatch repair proteins deficiency (p = 0.003), advanced grade (p = 0.015)], the correlation of distinct estimates (r = 0.708), the reproducibility of research (Kappa = 0.60-0.71), and the usefulness of cut-off value (area of under ROC = 0.800 [0.683-0.917]) were best. Then, survival analysis was performed with two better methods including Model A. In univariate analysis, low TIL with Model A was associated with worse OS (CD3, p < 0.001; CD8, p = 0.023) and RFS (CD3, p < 0.001; CD8, p = 0.005). Multivariate analyses confirmed low TIL with same method as an independent worse prognostic marker for OS (CD3, Hazard ratio [HR] = 1.42 [1.10-1.85], p = 0.005) and RFS (CD3, HR = 1.46 [1.17-1.83], p = 0.001; CD8, HR = 1.32 [1.05-1.64], p = 0.032). Conclusions: Our results confirm that low TIL is an independent worse prognostic marker in stage IIA (T3N0) CC and that the use of CD3 with Model A can contribute to improving the prognostication of early CCs.Öğe Rectal pyogenic granulomas: an uncommon cause of gastrointestinal bleeding(Aves, 2018) Devrim, Tuba; Utku, Ozlem Gul; Oguz, Dilek…Öğe Giant vascular eccrine spiradenoma of the leg: MR imaging findings(Elsevier Masson, Corporation Office, 2017) Aydin, G.; Balci, M.; Aydin, R.…Öğe Signet-ring cells in the skin: a case of late-onset cutaneous metastasis of gastric carcinoma and a brief review of histological approach(Pagepress Publ, 2016) Gunduz, Ozgur; Emeksiz, Mehmet Can; Atasoy, Pinar; Kidir, Mehtap; Yalcin, Selim; Demirkan, SerkanUp to 10% of patients with visceral malignancies develop skin metastases during their clinical course and these metastases constitute about 2% of all skin cancers. Skin metastasis may be the first sign of a clinically silent visceral cancer or represent recurrence of an internal malignancy. In both situations, they are associated with poor prognosis, which can partly be attributed to underdiagnosis. In this paper, a case of relapsing gastric adenocarcinoma, which manifested itself as asymptomatic cutaneous papules and nodules on a patient's head and neck, is reported and histopathological approach to the cutaneous lesions containing signet-ring cell is briefly reviewed.Öğe A Very Rare Cause of Chronic Back Pain: L1 Hemivertebra(Derman Medical Publ, 2016) Aydin, Ramazan; Aydin, Gulten…Öğe A unique cause of neck pain: peripheral primitive neuroectodermal tumor(Elsevier Science Inc, 2016) Aydin, Ramazan; Aydin, Gulten…Öğe Huge paravertebral masses in Proteus syndrome(Elsevier Science Inc, 2015) Aydin, Ramazan; Aydin, Gulten…Öğe First multifocal bullous fixed drug eruption due to etodolac(Elsevier Espana Slu, 2014) Kalkan, I. Koca; Kalpaklioglu, A. F.; Atasoy, P.; Karabulut, A. A.…Öğe Ischemic proctitis in a diabetic patient(Univ Catholique Louvain-Ucl, 2013) Sapmaz, Ferdane; Kalkan, Ismail Hakki; Guliter, Sefa; Atasoy, Pinar…Öğe Confluent and reticulated papillomatosis: favourable response to low-dose isotretinoin(Wiley, 2009) Erkek, E.; Ayva, S.; Atasoy, P.; Emeksiz, M. C.…Öğe Öğe Clinicopathologic challenge: Linear brown macules on the chest and arm(Wiley-Blackwell, 2008) Erkek, Emel; Bozdogan, Onder; Sanli, Cihat; Ozoguz, PinarWhat is your diagnosis?Öğe Vasculopathic skin lesions following epilation, leading to a discovery of hepatitis C virus infection(Wiley, 2007) Erkek, E.; Ayaşlıoğlu, E.; Erdoğan, S.; Bagci, Y.…Öğe Wood's light excites white fluorescence of type I hereditary punctate keratoderma(Blackwell Publishing, 2007) Erkek, E.; Ayva, S.…Öğe A case of cheilitis glandularis superimposed on oral lichen planus: successful palliative treatment with topical tacrolimus and pimecrolimus(Blackwell Publishing, 2007) Erkek, E.; Sahin, S.; Kilic, R.; Erdogan, S.…Öğe Fluorescence of hereditary type II punctate porokeratotic keratoderma (spiny keratoderma) with a Wood's light: Stars under the moonlight(Mosby-Elsevier, 2007) Erkek, Emel; Atasoy, Pinar…Öğe Kimura's disease in a Caucasian male treated with cyclosporine(Blackwell Publishing, 2005) Birol, A; Bozdogan, O; Keles, H; Kazkayasi, M; Bagci, Y; Kara, S; Kocak, M…Öğe Androgen receptor status in lesional and normal skin of patients with rosacea(Blackwell Publishing Ltd, 2004) Erkek, E.; Bozdogan, O.; Kocak, M.; Birol, A.; Atasoy, P.…Öğe Unilateral lesions in a patient with keratosis follicularis(European Acad Dermatology & Venereology, 2001) Erkek, E.; Atasoy, P.…Öğe Molecular markers in endometrial hyperplasia(2006) Atasoy, Pınar; Bozdoğan, ÖnderEndometrial hyperplasias show most of the molecular changes observed in endometrial carcinomas. PTH-rp, a growth factor, and LIF, a cytokine are over-expressed in endometrial hyperplasias, particularly in the complex atypical hyperplasia group. However, other growth factors and cytokines such as IGF-1, EGF, TNF-? and IL-1? are decreased in both types of hyperplasia. Similar to growth factors, growth factor receptors such as estrogen receptor and androgen receptor also increase in hyperplastic endometrium except in atypical hyperplasia group. The mutant form of RAS, KRAS, which is a signal transducer protein, acts in the pre-malignant phase of endometrial neoplasia. Another member of the RAS signaling pathway, BRAF, may also be altered in endometrial hyperplasias. Among the cell cycle regulators, basic abnormalities are observed in cyclin D1 and cyclin A. Both cyclins increase gradually from proliferative endometrium to endometrial hyperplasia and carcinoma. Rb2/p130 and cables are the two cycle-associated proteins, acting as a negative regulator that are down-regulated in the hyperplasia-carcinoma sequence. Molecular alteration of the ?-catenin gene in atypical hyperplasia and cancer, but not in simple or complex hyperplasia without atypia, suggests that it plays an important role in endometrial carcinogenesis. Derangements in the tumor suppressor gene, PTEN, are the most frequent genetic alteration observed in endometrial hyperplasias. PTEN inactivation seems to occur as an initiating event in endometrial carcinogenesis since it takes place in both atypical hyperplasia and carcinoma. Over-expression of BCL-2, an anti-apoptotic marker, is also associated with the generation of endometrial hyperplasia without atypia and it may be associated with the progression from endometrial hyperplasia to endometrial carcinoma. A significant number of endometrial hyperplasias harbor mutations in DNA mismatch repair genes, particularly methylation of the promoter region of hMLH1 gene. Hypermethylation of hMLH1 has been presumed to be an early event in the carcinogenesis of endometrial carcinoma. hTERT, Cathepsin D, MMPs and TIMPs have been studied less frequently but they also undergo significant alterations in endometrial hyperplasias. Overall, microsatellite instability and mutations of PTEN, KRAS and ?-catenin genes are the most common molecular alterations observed in endometrial hyperplasias. All these molecular markers are not only potential tumor markers for clinical use but also provide further evidence linking atypical hyperplasia and endometrial carcinoma, thus contributing to our understanding of endometrial carcinogenesis.
